LIDDS Investor Relations Material
Latest events
Q1 2025
28 May, 2025
Q4 2024
20 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from LIDDS
Access all reports
LIDDS AB is a Swedish pharmaceutical company that focuses on drug delivery technologies, particularly for cancer treatment. Its proprietary technology, NanoZolid, enables localized and controlled release of drugs for up to six months, reducing systemic side effects. LIDDS leverages this platform to develop its own oncology-focused pipeline, which includes candidates such as Nanodotax (a NanoZolid-formulated chemotherapy) and Nanoimod (a TLR9 agonist for cancer immunotherapy). The company's strategy also involves partnering with other pharmaceutical firms to enhance drug efficacy and safety using its drug delivery technology. LIDDS is headquartered in Uppsala, Sweden, and its shares are listed on the Stockholm Stock Exchange.
Latest articles
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
)
Costco Wholesale: The Model of Scalable Simplicity
Costco's rise from warehouse club to retail giant is built on low prices, scale efficiency, and a model designed for lasting customer value.
26 May 2025
Ticker symbol
LIDDS
Country
🇸🇪 Sweden